Dehydrocorydaline alkaloid has been shown to ameliorate atherosclerosis in ApoE-/-mice via inflammatory inhibition targeting through macrophage p65- and ERK1/2-mediated pathways [24]. This evidence concerns the gene APOE and atherosclerosis.